NCT03308474Recruiting
Myeloma Registry Platform (MYRIAM)
Clinical Research Platform for Molecular Testing, Treatment and Outcome of Patients With Multiple Myeloma (Myeloma Registry Platform; MYRIAM)
Source: ClinicalTrials.gov · Last updated 13 Jul 2026
Brief summary (registry, in English)
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with Multiple Myeloma in Germany.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2200 (estimated)
- First submitted
- 25 Sept 2017
- Start date
- 25 Sept 2017
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- iOMEDICO AG
- Diseases
- Multiple myeloma
- NCT number
- NCT03308474
What you commit to
- Study type: Observational
- Planned participants: 2200
- From 25 Sept 2017 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- No systemic therapy for myeloma
Other
- Patients already enrolled in studies that prohibit any participation in other studies
Who the study is looking for
- MM requiring systemic (first-, second- or third-line) treatment (closed for first-line / second-line recruitment)
- Age ≥ 18 years
- Written informed consent
- Patients participating in the PRO satellite: signing of informed consent and completion of baseline questionnaire before, but not more than eight weeks before the start of respective systemic treatment
- Patients not participating in the PRO satellite: signing of informed consent not later than four weeks after start of respective treatment, and not more than eight weeks before the start of respective systemic treatment
- Sufficient German language skills for participation in the PRO satellite
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Multiple sites all over germany Coordinator of this site? Confirm its status | Multiple Sites | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.